SS
CSTL icon

Steve Schonfeld’s Castle Biosciences CSTL Stock Holding History

Steve Schonfeld’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Sell
19,930
-22,483
-53% -$501K ﹤0.01% 1842
2026
Q1 		$1.04M Buy
42,413
+20,937
+97% +$686K 0.01% 1072
2025
Q4 		$835K Sell
21,476
-66,215
-76% -$2.13M ﹤0.01% 1197
2025
Q3 		$2M Buy
87,691
+19,765
+29% +$401K 0.01% 1033
2025
Q2 		$1.39M Buy
67,926
+8,255
+14% +$153K 0.01% 1169
2025
Q1 		$1.19M Buy
59,671
+44,371
+290% +$1.1M 0.01% 1210
2024
Q4 		$408K Sell
15,300
-40,700
-73% -$1.24M ﹤0.01% 1490
2024
Q3 		$1.6M Buy
56,000
+4,753
+9% +$121K 0.01% 986
2024
Q2 		$1.12M Sell
51,247
-114,194
-69% -$2.54M 0.01% 1160
2024
Q1 		$3.66M Buy
165,441
+4,141
+3% +$90.1K 0.02% 758
2023
Q4 		$3.48M Buy
161,300
+13,270
+9% +$234K 0.02% 622
2023
Q3 		$2.5M Buy
148,030
+110,500
+294% +$1.93M 0.02% 757
2023
Q2 		$515K Buy
37,530
+11,786
+46% +$239K ﹤0.01% 1214
2023
Q1 		$585K Sell
25,744
-31,715
-55% -$775K 0.01% 1122
2022
Q4 		$1.35M Sell
57,459
-108,935
-65% -$2.53M 0.01% 1000
2022
Q3 		$4.34M Sell
166,394
-1,369
-0.8% -$38.4K 0.04% 577
2022
Q2 		$3.68M Buy
167,763
+106,059
+172% +$2.46M 0.04% 555
2022
Q1 		$2.77M Buy
61,704
+20,590
+50% +$851K 0.02% 623
2021
Q4 		$1.76M Sell
41,114
-5,022
-11% -$262K 0.02% 739
2021
Q3 		$3.07M Buy
46,136
+18,723
+68% +$1.32M 0.03% 569
2021
Q2 		$2.01M Sell
27,413
-118
-0.4% -$7.79K 0.02% 707
2021
Q1 		$1.89M Buy
27,531
+19,531
+244% +$1.47M 0.02% 679
2020
Q4 		$538K Sell
8,000
-70,700
-90% -$3.83M 0.01% 1013
2020
Q3 		$4.05M Buy
78,700
+63,200
+408% +$2.81M 0.08% 342
2020
Q2 		$584K Buy
+15,500
New +$530K 0.02% 753

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's CSTL Position: Q2 2026 in Review

Steve Schonfeld reduced its Castle Biosciences (CSTL) stake by 53% in Q2 2026, selling an estimated $501K and leaving 19,930 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Steve Schonfeld first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.34M in Q3 2022. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Steve Schonfeld held 19,930 shares of Castle Biosciences worth $475K as of Q2 2026.
  • Steve Schonfeld sold 22,483 Castle Biosciences shares in Q2 2026, an estimated $501K.
  • Castle Biosciences made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1842 holding.
  • Steve Schonfeld first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Steve Schonfeld's Castle Biosciences position peaked at $4.34M in Q3 2022.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.